<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00556452</url>
  </required_header>
  <id_info>
    <org_study_id>UMCC 2007.055</org_study_id>
    <nct_id>NCT00556452</nct_id>
  </id_info>
  <brief_title>Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen</brief_title>
  <official_title>Phase I/II Study of Myeloablative Allogeneic Stem Cell Transplantation for Aggressive Hematologic Malignancies Using Clofarabine and Busulfan x 4 (Clo/BU4) Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goals of the study are (Phase I) to determine the appropriate dose for Clofarabine with
      Busulfan as a full-intensity conditioning (Clo/BU4 regimen) prior to transplant and then
      (Phase II) to investigate the safety and effectiveness of this regimen as a conditioning for
      stem cell transplant in the treatment of aggressive hematologic malignancies in subjects
      where more conventional approaches are failing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Transplants with stem cells collected from the blood of an unrelated donor (allo-HSCT) are
      being used more commonly for many blood cancers which are not curable with more conventional
      methods of chemotherapy. Although allo-HSCT has great potential, there are still high risks
      due to infections, graft-versus-host disease (GVHD), where the donor's cells attack the
      recipient's tissues as foreign, and due to toxic effects of the chemotherapy drugs given to
      prepare (or condition) the recipient's bone marrow for transplant.

      As a reduced intensity conditioning, a combination of Fludarabine and a lower dose of
      Busulfan (Flu/BU2) is one of the most popular regimens. Among full-intensity regimens, a
      combination of Fludarabine and standard-dose Busulfan (Flu/BU4) has been investigated
      recently and shown to be very well tolerated.

      Clofarabine, similar to Fludarabine, is known to have a stronger anti-tumor effect than
      Fludarabine and has shown promise in treating aggressive acute leukemias. In addition,
      evidence is that it is well-tolerated with manageable side effects especially in older
      subjects. Thus replacing Fludarabine with Clofarabine in a full-intensity transplant regimen,
      Clo/BU4 may provide a regimen with increased anti-tumor activity without adding significant
      risks of toxicity.

      The goals of the study are (Phase I) to determine the appropriate dose for Clofarabine with
      Busulfan as a full-intensity regimen (Clo/BU4) and then (Phase II) to investigate the safety
      and effectiveness of this regimen as a conditioning for HSCT in the treatment for aggressive
      hematologic malignancies, in subjects where more conventional approaches are failing.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Regimen Related Toxicities</measure>
    <time_frame>two years</time_frame>
    <description>The incidence of non-hematological toxicities (Common Terminology Criteria for Adverse Events (CTCAE) 3.0) from initiation of conditioning to Day + 30 or toxicities after day +30, possibly, probably or definitely related to conditioning for all patients treated with Clofarabine (independent of dose level).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>One-year Overall Survival Rate for AML</measure>
    <time_frame>1 year</time_frame>
    <description>Percent Overall Survival (OS) for at one year for subjects with Acute Myeloid Leukemia (AML).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Two-year Overall Survival for All Cases.</measure>
    <time_frame>2 years</time_frame>
    <description>Percent Overall Survival (OS) at two years for all patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Five Year Overall Survival for All Cases</measure>
    <time_frame>five years</time_frame>
    <description>The number of patients alive at 5 years</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Leukemia</condition>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Non-Hodgkin Lymphoma</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Clo/BU4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study will start at the 2nd dose level of three Clofarabine levels, in combination with Busulfan. The Clofarabine level that each subsequent patient is treated at is determined by a method using continual reassessment.
After pre-conditioning, subjects will receive a peripheral blood stem cell transplant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clofarabine/Busulfan x 4</intervention_name>
    <description>Clofarabine IV (dose levels)
1st dose level: 20 mg/m2/day x 5 days
2nd dose level: 30 mg/m2/day x 5 days
3rd dose level: 40 mg/m2/day x 5 days
Busulfan IV 3.2 mg/kg daily x 4 days</description>
    <arm_group_label>Clo/BU4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral blood stem cell transplant</intervention_name>
    <description>Peripheral blood stem cell transplant, after pre-conditioning drug treatment</description>
    <arm_group_label>Clo/BU4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total Lymphoid Irradiation</intervention_name>
    <description>Total Lymphoid Irradiation (TLI) of 4 Gy, if cord blood transplant</description>
    <arm_group_label>Clo/BU4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Disease Criteria

          -  Acute leukemia or chronic myelogenous leukemia in blastic crisis or accelerated phase,
             not in remission at the time of transplant

          -  Myelodysplastic syndrome, with more than 5% blasts in bone marrow at the time of
             transplant

          -  Hodgkin and Non-Hodgkin Lymphomas: Not in CR in PET scan or CT scan before transplant,
             or relapsed within 1 year from previous remission

          -  CLL not in remission

          -  Multiple Myeloma, not in remission

          -  Suitable donor available (related or unrelated)

        Age, Organ Function Criteria

          -  Age: ≤ 70 years

          -  Cardiac: LV Ejection Fraction ≥ 40% by MUGA or Echocardiogram

          -  Pulmonary: FEV1 and FVC ≥ 40% predicted, and DLCO (corrected for hemoglobin) ≥ 40% of
             predicted

          -  Renal: Adult population: serum creatinine ≤ 1.0 mg/dL (if serum creatinine &gt; 1.0
             mg/dL, then the estimated glomerular filtration rate (GFR) must be &gt; 60 mL/min/1.73 m2
             as calculated by the Modification of Diet in Renal Disease equation)

          -  Renal: Pediatric population: serum creatinine clearance ≥ 90 ml/min/1.73 m2 as
             calculated by the Schwartz formula for estimated GFR

          -  Hepatic: serum total bilirubin ≤ 2.0 mg/dl and AST / ALT ≤ ULN x 4

          -  Performance status: Karnofsky ≥ 70%

        Exclusion Criteria:

          -  Other active life-threatening cancer requiring treatment other than allo-HSCT

          -  HIV1 or HIV2 positive

          -  Uncontrolled medical or psychiatric disorder

          -  Uncontrolled viral or fungal infection

          -  Active CNS leukemia

          -  Non-compliant to medications

          -  No appropriate caregivers identified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Magenau, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan, Department of Internal Medicine, Blood and Marrow Transplant Program</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan, Department of Internal Medicine, Blood and Marrow Transplant Program</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48170</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2007</study_first_submitted>
  <study_first_submitted_qc>November 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 12, 2007</study_first_posted>
  <results_first_submitted>November 26, 2014</results_first_submitted>
  <results_first_submitted_qc>January 2, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 13, 2015</results_first_posted>
  <last_update_submitted>October 30, 2017</last_update_submitted>
  <last_update_submitted_qc>October 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Clofarabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients with relapsed or refractory hematologic malignancies not in remission received unmanipulated HSCT with CloBu4 conditioning from October 2007 to November 2009 at the University of Michigan. Patients received a clofarabine dose of 20mg/m^2, 30 mg/m^2 or 40 mg/m^2.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Clo/BU4 20mg/m^2</title>
          <description>Clofarabine/Busulfan x 4 : Clofarabine IV 20 mg/m^2/day x 5 days
Busulfan IV 3.2 mg/kg daily x 4 days
Peripheral blood stem cell transplant : Peripheral blood stem cell transplant, after pre-conditioning drug treatment.</description>
        </group>
        <group group_id="P2">
          <title>Clo/BU4 30mg/m^2</title>
          <description>Clofarabine/Busulfan x 4 : Clofarabine IV 30 mg/m^2/day x 5 days
Busulfan IV 3.2 mg/kg daily x 4 days
Peripheral blood stem cell transplant : Peripheral blood stem cell transplant, after pre-conditioning drug treatment.</description>
        </group>
        <group group_id="P3">
          <title>Clo/BU4 40mg/m^2</title>
          <description>Clofarabine/Busulfan x 4 : Clofarabine IV 40 mg/m^2/day x 5 days
Busulfan IV 3.2 mg/kg daily x 4 days
Peripheral blood stem cell transplant : Peripheral blood stem cell transplant, after pre-conditioning drug treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Experimental: Clo/BU4</population>
      <group_list>
        <group group_id="B1">
          <title>Clo/BU4 20mg/m^2</title>
          <description>Clofarabine/Busulfan x 4 : Clofarabine IV 20 mg/m^2/day x 5 days
Busulfan IV 3.2 mg/kg daily x 4 days
Peripheral blood stem cell transplant : Peripheral blood stem cell transplant, after pre-conditioning drug treatment.</description>
        </group>
        <group group_id="B2">
          <title>Clo/BU4 30mg/m^2</title>
          <description>Clofarabine/Busulfan x 4 : Clofarabine IV 30 mg/m^2/day x 5 days
Busulfan IV 3.2 mg/kg daily x 4 days
Peripheral blood stem cell transplant : Peripheral blood stem cell transplant, after pre-conditioning drug treatment.</description>
        </group>
        <group group_id="B3">
          <title>Clo/BU4 40mg/m^2</title>
          <description>Clofarabine/Busulfan x 4 : Clofarabine IV 40 mg/m^2/day x 5 days
Busulfan IV 3.2 mg/kg daily x 4 days
Peripheral blood stem cell transplant : Peripheral blood stem cell transplant, after pre-conditioning drug treatment.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="19"/>
            <count group_id="B4" value="46"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.5" lower_limit="14" upper_limit="61"/>
                    <measurement group_id="B2" value="54" lower_limit="18" upper_limit="68"/>
                    <measurement group_id="B3" value="51" lower_limit="1" upper_limit="67"/>
                    <measurement group_id="B4" value="53" lower_limit="1" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease</title>
          <description>The number of patients with each disease type.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Acute Myeloid Leukemia (AML)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic Myeloid Leukemia (CML)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute Lymphoblastic Leukemia (ALL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic Lymphocytic Leukemia (CLL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hodgkin Lymphoma (NHL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myelodysplastic Syndromes (MDS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple Myeloma (MM)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Regimen Related Toxicities</title>
        <description>The incidence of non-hematological toxicities (Common Terminology Criteria for Adverse Events (CTCAE) 3.0) from initiation of conditioning to Day + 30 or toxicities after day +30, possibly, probably or definitely related to conditioning for all patients treated with Clofarabine (independent of dose level).</description>
        <time_frame>two years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clo/Bu4</title>
            <description>Experimental: Clo/BU4</description>
          </group>
        </group_list>
        <measure>
          <title>Regimen Related Toxicities</title>
          <description>The incidence of non-hematological toxicities (Common Terminology Criteria for Adverse Events (CTCAE) 3.0) from initiation of conditioning to Day + 30 or toxicities after day +30, possibly, probably or definitely related to conditioning for all patients treated with Clofarabine (independent of dose level).</description>
          <units>toxicities</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Liver</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genito-Urinary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiopulmonary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neurologic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>One-year Overall Survival Rate for AML</title>
        <description>Percent Overall Survival (OS) for at one year for subjects with Acute Myeloid Leukemia (AML).</description>
        <time_frame>1 year</time_frame>
        <population>Patients with Acute Myeloid Leukemia (AML)</population>
        <group_list>
          <group group_id="O1">
            <title>Clo/BU4</title>
            <description>Study will start at the 2nd dose level of three Clofarabine levels, in combination with Busulfan. The Clofarabine level that each subsequent patient is treated at is determined by a method using continual reassessment.
After pre-conditioning, subjects will receive a peripheral blood stem cell transplant.
Total Lymphoid Irradiation : Total Lymphoid Irradiation (TLI) of 4 Gy, if cord blood transplant
Clofarabine/Busulfan x 4 : Clofarabine IV (dose levels)
1st dose level: 20 mg/m2/day x 5 days
2nd dose level: 30 mg/m2/day x 5 days
3rd dose level: 40 mg/m2/day x 5 days
Busulfan IV 3.2 mg/kg daily x 4 days
Peripheral blood stem cell transplant : Peripheral blood stem cell transplant, after pre-conditioning drug treatment</description>
          </group>
        </group_list>
        <measure>
          <title>One-year Overall Survival Rate for AML</title>
          <description>Percent Overall Survival (OS) for at one year for subjects with Acute Myeloid Leukemia (AML).</description>
          <population>Patients with Acute Myeloid Leukemia (AML)</population>
          <units>percent overall survival</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" lower_limit="34" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Two-year Overall Survival for All Cases.</title>
        <description>Percent Overall Survival (OS) at two years for all patients.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clo/BU4</title>
            <description>Study will start at the 2nd dose level of three Clofarabine levels, in combination with Busulfan. The Clofarabine level that each subsequent patient is treated at is determined by a method using continual reassessment.
After pre-conditioning, subjects will receive a peripheral blood stem cell transplant.
Total Lymphoid Irradiation : Total Lymphoid Irradiation (TLI) of 4 Gy, if cord blood transplant
Clofarabine/Busulfan x 4 : Clofarabine IV (dose levels)
1st dose level: 20 mg/m2/day x 5 days
2nd dose level: 30 mg/m2/day x 5 days
3rd dose level: 40 mg/m2/day x 5 days
Busulfan IV 3.2 mg/kg daily x 4 days
Peripheral blood stem cell transplant : Peripheral blood stem cell transplant, after pre-conditioning drug treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Two-year Overall Survival for All Cases.</title>
          <description>Percent Overall Survival (OS) at two years for all patients.</description>
          <units>percent overall survival</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28" lower_limit="17" upper_limit="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Five Year Overall Survival for All Cases</title>
        <description>The number of patients alive at 5 years</description>
        <time_frame>five years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clo/BU4</title>
            <description>Study will start at the 2nd dose level of three Clofarabine levels, in combination with Busulfan. The Clofarabine level that each subsequent patient is treated at is determined by a method using continual reassessment.
After pre-conditioning, subjects will receive a peripheral blood stem cell transplant.
Total Lymphoid Irradiation : Total Lymphoid Irradiation (TLI) of 4 Gy, if cord blood transplant
Clofarabine/Busulfan x 4 : Clofarabine IV (dose levels)
1st dose level: 20 mg/m2/day x 5 days
2nd dose level: 30 mg/m2/day x 5 days
3rd dose level: 40 mg/m2/day x 5 days
Busulfan IV 3.2 mg/kg daily x 4 days
Peripheral blood stem cell transplant : Peripheral blood stem cell transplant, after pre-conditioning drug treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Five Year Overall Survival for All Cases</title>
          <description>The number of patients alive at 5 years</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events occurring following study registration, but prior to beginning transplant therapy will not be reported. Post transplant, adverse events will be reported through day 100.</time_frame>
      <desc>Adverse events were analyzed for all patients that received Clofarabine, and not by Clofarabine dose received. All patients received the same study drug, Clofarabine.</desc>
      <group_list>
        <group group_id="E1">
          <title>Clo/Bu4</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrilation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Graft Versus Host Disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Disease Progression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Muscle Weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia/Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular Access Complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Bladder Hemmorhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Portal Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Arrythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Nausea/Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotention</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Transaminitis*</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Hyperbilirubiniemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Cholycytitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Siezure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Creatinine elevation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Hemorragic Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hand-foot syndrome</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Veno-Occlusive Disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. John Magenau</name_or_title>
      <organization>University of Michigan Cancer Center</organization>
      <phone>734/936-8785</phone>
      <email>johnmage@umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

